Artelo Biosciences announces presentations about ART12.11

Artelo Biosciences announced several presentations about ART12.11, Artelo’s proprietary cocrystal combination drug candidate, were delivered at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium held June 30 through July 5 in Salamanca, Spain. Andrew Yates, Chief Scientific Officer at Artelo, presented results from two studies entitled, “ART12.11, a Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Demonstrates a Unique Pharmacokinetic Profile,” and “ART12.11, a Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Demonstrates a Pharmacokinetic Profile Comparable with Epidiolex in Rats,” respectively. Matthew Jones, a member of the laboratory of Dr. Steven Laviolette at the University of Western Ontario, Canada, delivered the oral presentation “A Novel Cannabidiol: Tetramethylpyrazine (ART12.11, CBD:TMP) Cocrystal Improves the Efficacy and Bioavailability of Cannabidiol to Induce Anxiolytic and Anti-Depressant Effects.” Rodent pharmacokinetic data demonstrated that oral administration of an aqueous suspension of ART12.11 leads to increased plasma levels of CBD and its metabolites compared to CBD in the same formulation. This pharmacokinetic profile could not be replicated with coadministration of CBD and TMP. These results were obtained with an unoptimized aqueous suspension of ART12.11. Artelo is currently conducting drug formulation studies in order to optimize the oral solid delivery of ART12.11. In the pharmacodynamic study performed at the laboratory of Dr. Laviolette, oral administration of ART12.11 significantly reduced a range of anxiety and depressive symptoms in chronically stressed rats. These effects were not significantly observed with either Cannabidiol or Tetramethylpyrazine administered alone, or with a co-administration of CBD and TMP, despite CBD dosed alone with three times the amount of CBD used contained in ART12.11.